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Cyclin-dependent kinase 2 protects 
podocytes from apoptosis
Pauliina Saurus1, Sara Kuusela1, Vincent Dumont1, Eero Lehtonen1,2, 
Christopher L. Fogarty3,4,5, Mariann I. Lassenius3,4,5, Carol Forsblom3,4,5, Markku Lehto3,4,5, 
Moin A. Saleem6, Per-Henrik Groop3,4,5,7 & Sanna Lehtonen1
Loss of podocytes is an early feature of diabetic nephropathy (DN) and predicts its progression. We 
found that treatment of podocytes with sera from normoalbuminuric type 1 diabetes patients with 
high lipopolysaccharide (LPS) activity, known to predict progression of DN, downregulated CDK2 
(cyclin-dependent kinase 2). LPS-treatment of mice also reduced CDK2 expression. LPS-induced 
downregulation of CDK2 was prevented in vitro and in vivo by inhibiting the Toll-like receptor (TLR) 
pathway using immunomodulatory agent GIT27. We also observed that CDK2 is downregulated in the 
glomeruli of obese Zucker rats before the onset of proteinuria. Knockdown of CDK2, or inhibiting its 
activity with roscovitine in podocytes increased apoptosis. CDK2 knockdown also reduced expression 
of PDK1, an activator of the cell survival kinase Akt, and reduced Akt phosphorylation. This suggests 
that CDK2 regulates the activity of the cell survival pathway via PDK1. Furthermore, PDK1 knockdown 
reduced the expression of CDK2 suggesting a regulatory loop between CDK2 and PDK1. Collectively, 
our data show that CDK2 protects podocytes from apoptosis and that reduced expression of CDK2 
associates with the development of DN. Preventing downregulation of CDK2 by blocking the TLR 
pathway with GIT27 may provide a means to prevent podocyte apoptosis and progression of DN.
Glomerular diseases, including diabetic nephropathy (DN), are the leading causes of end-stage renal disease1. The 
pathophysiological mechanisms leading to the development of DN are poorly characterized, but recent studies 
indicate that podocyte injury is involved2. Podocytes are highly specialized cells that are required for normal 
glomerular integrity. One of the key features of progressive glomerulosclerosis is podocyte loss due to apoptosis 
or detachment. Podocyte loss has been reported in Pima Indians with type 2 diabetes (T2D) and also in patients 
with type 1 diabetes (T1D)3 or T2D with or without DN4–6. However, our knowledge of the pathophysiological 
mechanisms and proteins involved in the regulation of podocyte apoptosis remains limited.
Several factors have been shown to induce podocyte injury, including high glucose, reactive oxygen species 
(ROS), transforming growth factor beta (TGF-β ), angiotensin II, and lipopolysaccharides (LPS)/endotoxins7–12, 
that are lipid-soluble membrane components of the gram-negative bacteria. Interestingly, our previous study 
shows that normoalbuminuric T1D patients who progress to microalbuminuria have higher serum LPS activity 
than normoalbuminuric nonprogressors13. This indicates that high LPS activity in serum of patients with T1D is 
associated with the development of microalbuminuria13 and suggests that high LPS activity may induce podocyte 
injury in patients with T1D.
CDK2, a 42-kDa S-phase cyclin-dependent kinase, is activated by cyclin E in late G1 and by cyclin A in S 
phase where it controls G1/S passage14. CDK2 was believed to play an essential role in cell cycle progression, 
but CDK2 knockout mice are viable and have minimal phenotypic abnormalities15. It has been postulated that 
at least in vivo, other CDKs and cyclins may compensate for the missing CDKs16–18, however, this is still poorly 
understood. Nevertheless, it was shown that primary mouse embryonic fibroblasts isolated from CDK2 knockout 
mice show lower proliferation rates compared to wild type mouse embryonic fibroblasts15,19, suggesting that other 
CDKs are not able to efficiently compensate for the lack for CDK2. Previous studies addressing the role of CDK2 
in the kidney have concentrated on proliferative podocyte injury models. In experimental glomerulonephritis, 
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where podocytes re-enter the cell cycle and start to proliferate, inhibition of CDK2 has been shown to improve 
renal function by inhibiting proliferation of podocytes20. Inhibition of CDK2 has also been shown to decrease 
mesangial and glomerular endothelial cell proliferation in passive Heymann nephritis without aggravating podo-
cyte damage21. Since mature podocytes are terminally differentiated and therefore have a limited capacity to 
proliferate, the role of CDK2 in healthy, nonproliferating podocytes and nonproliferative glomerular diseases, 
such as DN, remains unclear.
Since phosphoinositide 3-kinase (PI3K)-dependent Akt signaling pathway has a pivotal role in regulating cell 
survival22–24, the molecules modulating its activity may play key roles in regulating podocyte apoptosis. Akt is 
known to phosphorylate CDK2 in vitro in 293T cells, and transient activation of the pathway is necessary for cell 
cycle progression25,26. Interestingly, CDK2 promotes activation of Akt by phosphorylating residues Ser477 and 
Thr479 under cell cycle progression in HeLa cells27. However, constitutively activated Akt/CDK2 pathway pro-
motes cell death26. Other studies point out that CDK2 may be either pro- or antiapoptotic apparently depending 
on the cellular status and the apoptotic stimulus28,29. We hypothesized that CDK2 could protect podocytes from 
apoptosis by promoting the activation of the Akt signaling pathway, and that podocyte injury induced by high 
LPS activity could downregulate CDK2 and subsequently enhance podocyte apoptosis.
Results
CDK2 is expressed in podocytes. Although CDK2 is widely expressed in human tissues, and Hiromura 
et al.30 showed CDK2 expression in both proliferating and differentiated mouse podocytes in vitro30, its localiza-
tion and exact function in the glomerular podocytes remains unclear. We immunoblotted isolated rat glomer-
ular and tubular fractions with an antibody against CDK2 and found that CDK2 is expressed in both glomeruli 
and tubules (Fig. 1A). Immunoblotting of lysates prepared from cultured human podocytes revealed that CDK2 
is expressed in both proliferating and differentiated podocytes (Fig. 1B), and immunofluorescence microscopy 
indicated that CDK2 concentrates in the nuclei in differentiated podocytes (Fig. 1C). Double labeling of mouse 
kidney sections for CDK2 and nephrin showed that CDK2 is expressed in podocytes, and is also detected in other 
glomerular cells (Fig. 1D–F). Double labeling of mouse kidney sections for CDK2 and Wilms tumor 1 (WT1) 
confirmed that CDK2 is expressed in the nuclei of podocytes (Fig. 1G–L). Omission of the primary antibody 
showed no signal in the nuclei in glomeruli confirming the specificity of the staining (Supplementary Fig. S1).
CDK2 expression is downregulated in the glomeruli of diabetic rats. Since the role of CDK2 in dia-
betes and DN has not been previously studied, we next investigated the expression level of CDK2 in the glomeruli 
of insulin resistant obese Zucker rats, a well-characterized model of T2D that shows similarities to early human 
DN31. At both 12 and 40 weeks of age, the obese rats had slightly higher blood glucose levels than the controls, 
but this did not reach statistical significance (Supplementary Table S1). At 12 weeks of age, the obese Zucker rats 
had higher urine albumin/creatine ratio than the lean controls, but the value was lower than in 40 weeks old lean 
rats (Supplementary Table S1), indicating that 12 weeks old rats did not have proteinuria. At 40 weeks, the obese 
rats had developed proteinuria (Supplementary Table S1). Quantitative Western blot analysis revealed that the 
expression level of CDK2 was decreased by 75% in the glomeruli of 12 weeks old (Fig. 2A,B) and by 45% in the 
glomeruli of 40 weeks old obese Zucker rats (Fig. 2A,C) when compared with lean controls.
CDK2 is downregulated in podocyte injury models in vitro. Since CDK2 expression was decreased 
in the glomeruli of obese Zucker rats compared to controls, we next investigated whether CDK2 is downregu-
lated in different podocyte injury models in vitro. Puromycin aminonucleoside (PA) and LPS are known induc-
ers of podocyte injury and apoptosis both in vitro and in vivo32–35. PA is a toxin used to induce experimental 
minimal change nephrosis in rats36, and LPS is an endotoxin from gram-negative bacteria that induces sepsis 
and proteinuria in mice and rats12,37,38. PA-treatment of cultured human podocytes for 48 hours decreased the 
expression level of CDK2 by 45% (Fig. 3A,B). Treatment of podocytes with LPS for 48 hours also decreased the 
expression level of CDK2 by 35% (Fig. 3A,C). Fluorescence activated cell sorting (FACS) with annexin V and 
7-Aminoactinomycin-D (7-AAD) double labelling, where annexin V is used as an apoptotic and 7-AAD as a 
necrotic marker, indicated that the level of apoptosis in control cells was 4%, whereas treatment with PA and LPS 
increased the level of apoptotic cells to 13% and 11%, respectively (Fig. 3D). The number of necrotic cells was not 
increased by LPS- or PA-treatment (2–3% in both).
Inhibition of the TLR pathway restores the expression of CDK2 and reduces podocyte apoptosis 
induced by LPS. Podocytes recognize LPS by Toll-like receptor 4 (TLR4)32,39,40. In order to study whether the 
LPS-induced reduction in the expression of CDK2 is restored by TLR blockage, podocytes were treated with TLR 
pathway inhibitor 4,5-Dihydro-3-phenyl-5-isoxazoleacetic acid (GIT27) before addition of LPS to the media. 
Treatment of podocytes with LPS reduced the expression of CDK2 by 40% and increased apoptosis as determined 
by FACS analysis of Annexin V labeled cells (Fig. 4A–C). Co-treatment with GIT27 restored the expression of 
CDK2 and prevented podocyte apoptosis induced by LPS (Fig. 4A–C). Treatment with GIT27 alone had no effect 
to the expression level of CDK2 (Supplementary Figure S2).
To test the hypothesis that high serum LPS activity in T1D patients reduces the expression of CDK2, we sup-
plemented the culture medium of human podocytes with sera from normoalbuminuric patients with high or low 
LPS activity. Patient data is described in Supplementary Table S2. Quantitative Western blotting revealed that the 
expression level of CDK2 was downregulated by 23% after 72h exposure to serum from patients with high LPS 
activity when compared to cells treated with serum from patients with low LPS activity (Fig. 4D,E). Sera with high 
LPS activity also increased apoptosis as indicated by increased level of cleaved caspase-3 (Fig. 4F). In order to con-
firm that CDK2 downregulation is mediated by endotoxins, cultured human podocytes were treated with GIT27 
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Figure 1. CDK2 is expressed in podocytes. (A) Immunoblot of rat glomerular and tubular fractions shows that 
CDK2 is expressed in glomeruli and tubuli. Tubulin is included as a loading control. (B) Immunoblot of cultured 
human podocytes shows that CDK2 is expressed in both proliferating and differentiated podocytes. Tubulin 
is included as a loading control. (C) Immunofluorescence microscopy indicates that CDK2 localizes mainly in 
the nuclei in differentiated human podocytes. (D–F) Perfused mouse kidney sections stained with CDK2 (D) 
and nephrin (E) antibodies shows that CDK2 is expressed in mouse glomerulus. (G–L) Perfused mouse kidney 
sections stained with CDK2 (G,J) and WT1 (H,K) antibodies shows that CDK2 concentrates in nuclei (arrows) 
in podocytes as visualized in merged image (I,L). Scale bars: (C) 12 μ m, (D–I) 25 μ m, (J–L) 12 μ m.
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before adding the media with sera from normoalbuminuric patients with high serum LPS activity. Co-treatment 
with GIT27 restored the expression of CDK2 and reduced podocyte apoptosis (Fig. 4D–F).
High glucose decreases CDK2 expression in vitro. We also tested whether high glucose treatment 
reduces CDK2 expression in cultured human podocytes, since high glucose has been shown to induce podocyte 
apoptosis41,42. The expression level of CDK2 was decreased slightly, by 13%, in podocytes treated with high glu-
cose compared to podocytes cultured in normal glucose (Supplementary Fig. S3).
Inhibition of the TLR pathway restores the expression of CDK2 in kidney and prevents podo-
cyte foot process widening induced by LPS in mice. To investigate the effect of LPS on CDK2 expres-
sion in vivo and whether lowered CDK2 expression can be rescued by inhibiting the TLR pathway as in vitro, we 
used LPS to induce podocyte injury in BALB-C mice as previously described43. Mice were treated with either 
GIT27 or its vehicle 24 h prior and 2 h after LPS challenge. Control mice received vehicle only. Albuminuria, 
CDK2 expression and podocyte foot process effacement were analyzed 24 h after LPS challenge. LPS increased 
urinary albumin excretion from 0.16 ± 0.15 mg/mmol to 21.27 ± 10.01 mg/mmol (p < 0.05). LPS also decreased 
the expression of CDK2 in mouse kidneys as observed by immunoblotting of kidney cortical lysates (Fig. 5A,B). 
The two bands observed by immunoblotting apparently represent differentially phosphorylated forms of CDK2 
as previously described44. In addition, immunohistochemistry revealed reduction of CDK2 in the glomeruli of 
LPS-treated mice (Supplementary Fig. S4A,B). Co-treatment with GIT27 prevented downregulation of CDK2 
in the kidney (Fig. 5A,B) and glomeruli (Supplementary Fig. S4A,C). GIT27 also decreased urinary albumin 
excretion from 21.27 ± 10.01 mg/mmol to 10.88 ± 1.85 mg/mmol, but this did not reach statistical significance. 
Electron microscopy analysis of control, LPS-treated and LPS- and GIT27-treated mouse kidneys revealed 
Figure 2. CDK2 is downregulated in the glomeruli of obese Zucker rats. (A) The expression of CDK2 is 
decreased in the glomeruli of 12 and 40 weeks old obese Zucker rats compared to lean controls. Tubulin is 
included as a loading control. (B) Quantification of CDK2 in the glomeruli of 6 individual lean and 6 individual 
obese 12 weeks old Zucker rats shows lower expression of CDK2 in the glomeruli of obese Zucker rats.  
(C) Quantification of CDK2 in the glomeruli of 6 individual lean and 6 individual obese 40 weeks old Zucker 
rats shows that the expression of CDK2 is lower in the glomeruli of obese Zucker rats. In (A), glomeruli were 
isolated, lysed and immunoblotted with anti-CDK2 IgGs. Data are presented as mean ± SEM (n = 6 per group). 
*p < 0.05, ***p < 0.001 vs. lean group.
Figure 3. CDK2 is downregulated in podocyte injury models in vitro. (A) Representative immunoblot for 
CDK2 after PA- and LPS-treatments. Tubulin is included as a loading control. (B) Quantification of CDK2 after 
PA-treatment shows a decrease in CDK2 expression level in cultured human podocytes. (C) Quantification of 
CDK2 after LPS-treatment shows a decrease in CDK2 expression level in cultured human podocytes. (D) Flow 
cytometry of cultured human podocytes stained with annexin V and 7-AAD double labeling, where annexin 
V is used as an apoptosis and 7-AAD as a necrosis marker, confirms that PA- and LPS-treatments increase 
podocyte apoptosis. The experiments were performed three times with three replicates in each experiment. 
Data are presented as mean ± SD. *p < 0.05, ***p < 0.001 vs. control group.
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Figure 4. Inhibition of the TLR pathway prevents downregulation of CKD2 and induction of apoptosis in 
cultured human podocytes treated with LPS or with human sera with high LPS activity. (A) Representative 
immunoblot for CDK2 of LPS-treated podocytes with or without GIT27 treatment. Tubulin is included as 
a loading control. (B) Quantification of CDK2 shows that co-treatment of podocytes with LPS and GIT27 
prevents downregulation of CDK2. The experiment was performed three times with three replicates in each 
experiment. Data are presented as mean ± SD. *p < 0.05 vs. LPS group. (C) Flow cytometry of podocytes stained 
for Annexin V confirms that co-treatment of podocytes with GIT27 and LPS prevents induction of apoptosis. 
The experiment was performed three times with three replicates in each experiment. Data are presented as 
mean ± SD. ***p < 0.001, ****p < 0.0001 vs. LPS group. (D) Representative immunoblot for CDK2 in cultured 
human podocytes treated with sera with low or high LPS activity, and with or without GIT27 co-treatment. 
Tubulin is included as a loading control. (E) Quantification of CDK2 from podocytes treated with sera with 
high or low LPS activity (n = 6 each), or treated with sera with high LPS activity in the presence of GIT27 
(n = 6). The expression of CDK2 was lower after treatment with sera with high LPS activity than with low LPS 
activity. GIT27-treatment prevented downregulation of CDK2 induced by high LPS activity. The experiment 
was performed three times. Data are presented as mean ± SD. *p < 0.05, vs. high LPS group. (F) Quantification 
of In-Cell Western of cleaved caspase-3 in podocytes treated with sera with high or low LPS activity with or 
without GIT27 treatment shows that the expression of cleaved caspase-3 was higher after treatment with high-
LPS sera compared to treatment with low-LPS sera. GIT27-treatment prevented the induction of apoptosis. 
DRAQ5TM was used for normalization. Treatments were performed with sera from individual patients (n = 6 
per group). The experiment was performed three times with 32 replicates in each group. Data are presented as 
mean ± SD, ****p < 0.0001 vs. high LPS group.
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irregular widening of the podocyte foot processes in the LPS-treated mice (Fig. 5C,D,F). This was prevented by 
GIT27 co-treatment (Fig. 5D–  F).
Knockdown of CDK2 by shRNAs or inhibiting the activity of CDK2 by roscovitine increases 
apoptosis of cultured human podocytes. Reduction of the expression level of CDK2 in podocytes after 
treatment with apoptosis-inducing agents PA and LPS suggests that CDK2 could be involved in the regulation 
of apoptosis in podocytes. To confirm this hypothesis, CDK2 was knocked down in cultured human podocytes 
using two different lentiviral small hairpin RNAs (shRNAs), CDK2A and CDK2B. Immunoblotting showed that 
both shRNAs lowered CDK2 protein level by 80% ± 5% and the level of active, phosphorylated CDK2 (Thr160) 
by 70% ± 0.8% 48 h after infection compared to podocytes infected with viruses carrying the empty vector shRNA 
(Fig. 6A,B,C). FACS-analysis with annexin V and 7-AAD confirmed that the level of apoptosis was increased 
from 5–7% in podocytes infected with the empty vector to 15–17% in podocytes infected with CDK2A or CDK2B 
shRNAs (Fig. 6D). The level of apoptosis in untreated control cells was similar to cells infected with the empty 
vector (4–8% in both), and the rate of necrotic cells was not increased by CDK2 knockdown (0.3% in both CDK2 
shRNA-infected and empty vector-infected podocytes).
To further confirm the role of CDK2 in podocyte apoptosis, we inhibited the kinase activity of CDK2 by using 
roscovitine that is a well known inhibitor of CDK2 activity14,21. Inhibition of CDK2 activity using roscovitine in 
cultured human podocytes decreased the phosphorylation level of CDK2 (Thr160) by 49 ± 15% and the expres-
sion level of CDK2 by 10% ± 7%. Interestingly, roscovitine increased apoptosis of podocytes as visualized by 
69% ± 18% increase in the expression level of cleaved caspase-3 (Fig. 6E). Collectively, either depletion of CDK2 
or inhibition of its kinase activity enhances podocyte apoptosis.
Knockdown of CDK2 downregulates cyclin E and inhibits the antiapoptotic and stimulates 
the proapoptotic pathways. In order to study the molecular pathways involved in apoptosis induced 
by low CDK2 expression, we examined the expression of cyclin E, an activator of CDK214,15, cyclin-dependent 
kinase 4 (CDK4), another cyclin-dependent kinase, and apoptosis-associated kinases Akt and p38MAPK, after 
CDK2 knockdown. We found that CDK2 knockdown reduced the expression of cyclin E by 45–55% (Fig. 7A,B). 
CDK2 knockdown had no effect on CDK4 expression confirming the specificity of the knockdown (Fig. 7C,D). 
Figure 5. Inhibition of the TLR pathway prevents LPS-induced downregulation of CDK2 and podocyte 
foot process widening in BALB-C mouse kidneys. (A) Representative immunoblot for CDK2 in control, LPS-
treated and LPS- and GIT27-treated mouse kidney cortical lysates. Tubulin is included as a loading control.  
(B) Quantification of CDK2 in mouse kidney cortical lysates shows that co-treatment of mice with LPS 
and GIT27 prevents LPS-induced downregulation of CDK2 (n = 6/treatment group). Data are presented as 
mean ± SEM. *p < 0.05, **p < 0.01 vs. LPS group. (C) Electron microscopy of control mouse kidney shows 
podocyte foot processes (arrows) regularly lining the glomerular basement membrane around capillary loops. 
(D) LPS-treatment induces podocyte foot process widening (arrows). (E) GIT27 co-treatment prevents LPS-
induced podocyte foot process widening (arrows). Scale bar (C–E): 2 μ m. (F) Quantification of podocyte foot 
process width confirms that LPS causes foot process widening which is prevented by GIT27 co-treatment. 
Foot process width was calculated from 4 animals per group, 3 glomeruli per animal and 3 capillary loops per 
glomeruli. Data are presented as mean ± SEM. ****p < 0.0001 vs. LPS group. In (A), mouse kidney cortices were 
lysed and immunoblotted with anti-CDK2 IgG.
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In addition, knockdown of CDK2 reduced the phosphorylation level of Akt on Ser473 by 35–40% (Fig. 7E,F), 
and increased the activation of the proapoptotic p38 MAPK pathway by inducing phosphorylation of p38 by 
150–180% (Fig. 7G,H).
To investigate the involvement of proteins of the intrinsic apoptotic pathway in apoptotic processes involving 
CDK2, we studied the expression level of BCL-2 and BAX after CDK2 knockdown. Depletion of CDK2 decreased 
the level of BCL-2 by 80% and increased the level of BAX by 30–35% (Fig. 7I,J) indicating that the expression level 
of CDK2 influences the expression levels of the pro-survival protein BCL-2 and the pro-apoptotic protein BAX.
Knockdown of CDK2 reduces PDK1 expression and PDK1 knockdown reduces CDK2 expres-
sion. Since downregulation of CDK2 induced apoptosis and reduced phosphorylation of Akt, we next ana-
lyzed whether 3-phosphoinositide dependent protein kinase-1 (PDK1), which we previously showed to function 
as an activator of the Akt cell survival pathway in podocytes43, is linked to podocyte apoptosis induced by CDK2 
depletion. We knocked down either CDK2 or PDK1 using lentiviral shRNAs. Knockdown of CDK2 reduced the 
expression of PDK1 by 48% (Fig. 8A,B), which suggests that CDK2 affects the PI3K/Akt –mediated cell survival 
pathway by regulating PDK1 expression. PDK1 knockdown, in turn, reduced the expression of CDK2 by 33% 
(Fig. 8C,D) suggesting a regulatory loop between CDK2 and PDK1 (Fig. 8E).
Figure 6. Knockdown of CDK2 by shRNAs increases apoptosis in cultured human podocytes. (A) 
Representative immunoblot for CDK2 and phospho-CDK2 (pCDK2, Thr160) in CDK2 knockdown cells. 
Podocytes were infected using two different shRNA constructs targeting CDK2 (CDK2A, CDK2B). Empty 
vector (vector) shRNA served as a control. Tubulin is included as a loading control. (B) CDK2 protein level is 
significantly decreased by both shRNAs compared to empty vector shRNA. (C) Quantification of phospho-
CDK2 shows that the phosphorylation level of CDK2 is downregulated after knockdown of CDK2. The 
experiments (A,B) were performed three times with three replicates in each experiment. (D) Flow cytometry 
of podocytes stained with annexin V confirms that CDK2 knockdown increases podocyte apoptosis. The 
experiment was performed three times with three replicates in each experiment. Data are presented as 
mean ± SD. ***p < 0.001 vs. vector group. (E) Quantification of In-Cell Western of phospho-CDK2, CDK2 
and cleaved caspase-3 in podocytes treated or not with 25 μ M roscovitine shows that the expression of 
phosphorylated CDK2 and CDK2 are decreased and the expression of cleaved caspase-3 is higher after 
treatment with roscovitine compared to control. DRAQ5TM was used for normalization. The experiment was 
performed three times, with 24 replicates per group. Data are presented as mean ± SD, ***p < 0.001 vs. control 
group.
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Discussion
Numerous studies have reported that podocyte loss due to apoptosis or detachment is an important indicator 
whether podocyte injury leads to proteinuria and progressive glomerulosclerosis in diabetic and non-diabetic 
renal disease5,45,46. Therefore preventing podocyte loss in patients with glomerular disease is an important ther-
apeutic target. In this study we found that the cell cycle regulatory protein CDK2 is expressed in the glomerular 
podocytes and protects podocytes from apoptosis. Previous studies reported negligible expression of CDK2 in 
glomeruli47,48. The difference between these studies and ours may be due to different antibodies and experimental 
conditions used. Furthermore, the regulation of CDK2 is more complex than regulation of its absolute expression 
level, as CDK2 is controlled by cyclin-dependent kinase inhibitors30,48, and for example, to regulate cell cycle, 
CDK2 is activated by complex formation with cyclin A or E and phosphorylation in the activation loop49.
We observed that CDK2 is downregulated in the glomeruli of obese Zucker rats already at an early stage 
before the rats develop proteinuria or glomerular apoptosis50–52. We also found that downregulation of CDK2 
Figure 7. CDK2 knockdown inhibits cyclin E and the antiapoptotic pathways and stimulates the pro-
apoptotic pathways in cultured human podocytes. (A) Immunoblot of cyclin E and CDK2 after knockdown 
of CDK2 with two different shRNA constructs (CDK2A and CDK2B) in cultured podocytes. Empty vector 
(vector) served as a control. Tubulin is included as a loading control. (B) Quantification of cyclin E shows 
that the expression level of cyclin E is downregulated after knockdown of CDK2. (C) Immunoblot of CDK4 
after CDK2 knockdown in cultured podocytes. Tubulin is included as a loading control. (D) Quantification 
of CDK4 shows that the expression level of CDK4 does not change after CDK2 knockdown confirming the 
specificity of the knockdown. (E) Immunoblot assay of phosphorylated Akt (pAkt) in podocytes after CDK2 
knockdown. Total Akt is included as a loading control. (F) Quantification of phosphorylated Akt shows that 
CDK2 knockdown decreases Akt activity in cultured podocytes. (G) Immunoblot of phosphorylated p38 
(pp38) in podocytes after CDK2 knockdown. Total p38 is included as a loading control. (H) Quantification of 
phosphorylated p38 shows that CDK2 knockdown increases p38 activity in cultured podocytes. (I) Immunoblot 
of BCL-2 and BAX after knockdown of CDK2 in cultured podocytes. Tubulin is included as a loading control. 
(J) Quantification of BCL-2 and BAX shows that the expression level of BCL-2 is downregulated and BAX 
upregulated after knockdown of CDK2. Each experiment was performed three times with three replicates in 
each experiment. Data are presented as mean ± SD. ns: non significant, *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
vector group.
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Figure 8. CDK2 knockdown reduces PDK1 expression and PDK1 knockdown reduces CDK2 expression 
in cultured human podocytes. (A) Representative immunoblot for PDK1 showing decreased PDK1 expression 
after CDK2 knockdown. Tubulin is included as a loading control. (B) Quantification of PDK1 shows that 
CDK2 knockdown decreases PDK1 expression in cultured podocytes. (C) Representative immunoblot for 
CDK2 after PDK1 knockdown in podocytes showing decreased CDK2 expression. Tubulin is included as a 
loading control. (D) Quantification of CDK2 shows that PDK1 knockdown decreases CDK2 expression in 
www.nature.com/scientificreports/
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or inhibition of its kinase activity with roscovitine in cultured podocytes induces apoptosis further supporting a 
protective role for CDK2. Thus far CDK2 has been assumed to play a role in proliferative podocyte injury models, 
e.g., passive Heymann nephritis and experimental crescentic glomerulonephritis, where podocyte proliferation 
aggravates the decline in renal function20,21. In these models, inhibition of CDK2 limited podocyte proliferation 
and improved renal function20,21. It thus appears that the consequences of inhibiting or downregulating CDK2 in 
podocytes depend on the differentiation state of the cells. In proliferative glomerular diseases, inhibition of CDK2 
is beneficial to podocytes. However, in differentiated podocytes and nonproliferative glomerular diseases, such 
as DN, inhibition of CDK2 in podocytes may lead to or aggravate podocyte injury. These data indicate that the 
function of CDK2 in podocytes needs to be tightly regulated depending on the state of differentiation.
We observed that CDK2 is downregulated in experimental podocyte injury models in vitro, including high 
glucose, PA- and LPS-induced injury. Of these, the LPS-induced podocyte injury is especially interesting in rela-
tion to DN, as we found previously that high serum LPS activity in normoalbuminuric patients with T1D predicts 
the progression of the disease13 and that the incidence of bacterial infections also correlates with the severity 
of DN in Finnish patients with T1D53. Interestingly, treatment of podocytes with sera with high LPS activity 
downregulated CDK2, indicating that sustained expression of CDK2 may be clinically significant in maintaining 
normal podocyte function. Still, we cannot rule out that some other factors in human sera in addition to LPS 
could contribute to downregulation of CDK2. However, high glucose did not contribute to increased apoptosis 
or decreased CDK2 expression in podocytes treated with human sera, since blood glucose values were similar in 
patients with low and high serum LPS.
The results showing that human sera with high LPS decreases CDK2 expression also provides options for 
treatment via blockade of the TLR pathway, as LPS binds to TLR4 that is expressed in podocytes12,32,39. Of note, 
TLR4 has been shown to be necessary for LPS responsiveness as mice in which TLR4 is mutated40,54, or mice that 
lack TLR455, are low responders to LPS. Jialal et al.56 also demonstrated that in streptozotocin-induced diabetic 
mice with global TLR4 deficiency, renal inflammation, podocytopathy and fibrosis are improved56. Indeed, we 
found that in both cultured podocytes in vitro and mice in vivo, treatment with the TLR pathway inhibitor GIT27 
prevented LPS-induced downregulation of CDK2.
Phosphorylation of Akt is central to the activation of the antiapoptotic PI3K/Akt cell survival pathway. CDK2 
locates downstream of Akt, but is known to phosphorylate Akt on Ser477 and Thr479 promoting its activation 
at a specific stage during cell cycle progression27. We found that knockdown of CDK2 in podocytes reduced 
phosphorylation of Akt on Ser473 and induced apoptosis. In addition, inhibiting the kinase activity of CDK2 
by roscovitine induced apoptosis in podocytes. Supporting our finding, inhibition of CDK2 in HeLa cells by 
roscovitine led to a significant reduction in Akt phosphorylation in different phosphorylation sites, including 
Ser47327. Furthermore, CDK2 associates with cyclin A2, and in brain-specific cyclin A2 knockout mice, Akt 
phosphorylation on Ser477 and Thr479 was inhibited in olfactory bulbs and led to elevated cleavage of caspase-3 
and increased cellular apoptosis27. This further supports the idea that in the brain, CDK2/cyclin A2 complex 
enhances cellular survival by promoting activation of Akt. In addition, we noticed that knockdown of CDK2 led 
to downregulation of cyclin E, which is an activator CDK249 confirming the association of cyclin E and CDK2 
expression in podocytes.
PDK1 is the key mediator of the activity of the PI3K/Akt pathway downstream of PI3K and upstream of Akt 
and serves as a major regulator in Akt signaling57. We have previously shown that PDK1 protects podocytes 
against apoptosis43. Interestingly, we observed that knockdown of CDK2 in podocytes reduces the expression of 
PDK1 providing a novel mechanistic insight how CDK2, in addition to directly phosphorylating Akt27, regulates 
the activity of the cell survival pathway. Furthermore, we observed that knockdown of PDK1 reduces the expres-
sion of CDK2, suggesting a regulatory loop between these two proteins (Fig. 8E). Thus one can envisage that 
downregulation of CDK2 may further enhance the reduction of its own level via downregulation of PDK1. This 
apparently further aggravates the reduced activity of the PI3K/Akt pathway.
In summary, we demonstrated a novel function for CDK2 in podocytes as an antiapoptotic protein. 
Downregulation of CDK2 in the glomeruli of obese Zucker rats prior to significant glomerular apoptosis43 and 
development of albuminuria further suggest that downregulation of CDK2 plays a role in the diabetic kidney 
complication. The data also indicate a potential role for the blockade of the TLR pathway in the treatment of DN. 
The fact that the TLR pathway inhibitor GIT27 has been shown to be non-toxic and its administration both i.p 
and p.o. are equally efficient, supports its potential for clinical use58.
Materials and Methods
Animal studies. Male wild type C57BL/6JOlaHsd mice (Harlan Laboratories, Indianapolis, IN) were used to 
study CDK2 expression. At time of sacrifice, mice were perfused with phosphate buffered saline (PBS) for 20 min-
utes at room temperature (RT) before collecting the kidneys. Glomeruli were isolated by graded sieving59 from 
male Sprague-Dawley or obese (fa/fa) and lean (fa/+ ) Zucker rats (Crl:ZUC-Leprfa, Charles River Laboratories, 
cultured podocytes. Each experiment was performed three times with three replicates in each experiment. 
Data are presented as mean ± SD. *p < 0.05, **p < 0.01 vs. vector group. (E) Schematic illustration linking 
CDK2 to the PI3K-dependent Akt signalling in podocyte apoptosis. PI3K stimulates PDK1, which activates 
Akt by phosphorylation of PIP2 to PIP3. PDK1 also induces CDK2 expression and CDK2 induces PDK1 
expression. CDK2 reduces p38 phosphorylation and BAX expression and induces BCL-2 expression 
and Akt phosphorylation. In addition, Akt is known to activate CDK2. Induced BCL-2 expression and 
Akt phosphorylation protect podocytes from apoptosis. PIP2: phosphoinositol(4,5)biphosphate; PIP3: 
phosphoinositol(3,4,5)trisphosphate.
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Sulzfeld, Germany). Blood glucose and urinary albumin to creatinine ratio of the Zucker rats were measured 
as previously described51. Female BALB-C mice (BALB/cAnNCrl) were purchased from Scanbur (Karlslunde, 
Denmark). Mice were devided to three groups and treated with LPS (Sigma-Aldrich, St. Louis, MO) and GIT27 
(Tocris Bioscience, Bristol, UK), LPS and PBS (vehicle for both LPS and GIT27), or PBS only (n = 6 in each 
group). Mice were injected intraperitoneally with GIT27 at a dose of 20 mg/kg or equal volume of vehicle. 24 h 
after GIT27 injection, LPS was administered at a dose of 12 mg/kg intraperitoneally. Control mice received vehi-
cle alone. Another dose of GIT27 or vehicle was injected 2 h after LPS administration. Mice were sacrificed and 
kidneys harvested and processed for immunohistochemistry or electron microscopy 24 h after LPS injection. 
Animal procedures were approved by the National Animal Experiment Board, and all animal experiments were 
performed according to approved guidelines.
Cell culture. Immortalized human podocytes60 were maintained as previously decribed in RPMI media 
supplemented with 10% fetal bovine serum (FBS), 1% glutamine, and insulin, transferrin and sodium selenite 
(ITS) at + 33 °C for proliferation. For differentiation, podocytes were transferred to non-permissive conditions 
at + 37 °C for 14 days. HEK293FT cells (Invitrogen, Carlsbad, CA) were maintained in DMEM medium, sup-
plemented with 10% FBS, ultraglutamine, penicillin and streptomycin. Media, FBS and ITS were obtained from 
Sigma-Aldrich and ultraglutamine from Lonza (Basel, Switzerland).
Immunoblotting. Immunoblotting was performed as decribed in51. Primary antibodies used were mouse 
monoclonal anti-CDK2 (Santa Cruz Biotechnology, Dallas, Texas, USA), rabbit polyclonal anti-CDK2 (Abcam, 
Cambridge, UK), rabbit polyclonal anti-phospho-CDK2 (Cell Signaling Technology, Danvers, MA), rabbit pol-
yclonal anti-cyclin E2 (Cell Signaling Technology), rabbit polyclonal anti-CDK4 (Cell Signaling Technology), 
rabbit polyclonal anti-p38 MAPK, rabbit polyclonal anti-phospho-p38 MAPK (Thr180/Tyr182), rabbit polyclonal 
anti-phopho-Akt (Ser473), rabbit polyclonal anti-cleaved caspase-3 (Cell Signaling Technology), mouse mono-
clonal anti-Pan Akt (R&D Systems, Minneapolis, MN), rabbit polyclonal anti-Bax and rabbit polyclonal anti-Bcl2 
(Abcam) and mouse monoclonal anti-tubulin IgGs (Sigma-Aldrich). Alexa Fluor 680 (Invitrogen) and IRDye 
800 (LI-COR, Lincoln, NE) donkey anti-rabbit, anti-goat or anti-mouse IgGs were used as secondary antibodies. 
Detection and quantification was performed with an Odyssey Infrared Imager (LI-COR). Full Western blots with 
antibodies against CDK2 and phospho-CDK2 are shown in Supplementary Figure S5.
Immunofluorescence microscopy. Differentiated human podocytes were fixed with 2% paraformalde-
hyde (Electron Microscopy Sciences, Hatfield, PA) in PBS and permeabilized with 0.1% Triton X-100 in PBS. 
Podocytes were blocked with CAS-block (Invitrogen), stained with mouse anti-CDK2 (Santa Cruz Biotechnology) 
for one hour at RT in ChemMate (Dako Cytomation, Glostrup, Denmark), washed with PBS and incubated 
with DyLight 488 donkey anti-mouse IgG (Abcam) for one hour in ChemMate (Dako Cytomation). Perfused 
mouse kidney samples were fixed with 10% formaldehyde and embedded in paraffin. Deparaffinized sections 
were blocked with CAS-block (Invitrogen), incubated with rabbit anti-CDK2 (Abcam), guinea pig anti-nephrin 
(Progen Biotechnik GmbH, Heidelberg, Germany) or mouse anti-WT1 (Upstate, New York, USA) IgGs over-
night at + 4 °C in ChemMate (Dako Cytomation), washed with PBS and incubated with AlexaFluor 555 donkey 
anti-rabbit (Invitrogen), DyLight 488 donkey anti-quinea pig IgGs (Jackson Immuno Research Laboratories Inc., 
West Grove, PA) or DyLight 488 donkey anti-mouse IgGs (Jackson Immuno Research Laboratories Inc.). Samples 
were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and examined with Leica TCS CARS SP8 
confocal microscope (Leica Microsystems CMS GmbH, Mannheim, Germany).
Induction and detection of apoptosis. Differentiated human podocytes were exposed to puromycin 
aminonucleoside (PA, Sigma-Aldrich, 50 μ g/ml) or lipopolysaccharide (LPS, 100 ng/ml Escherichia coli 0111:B4, 
Sigma-Aldrich) for 48 hours. The activity of LPS (100 ng/ml) in cell culture media was measured as described in13, 
and was shown to be 1.7 EU/ml. GIT27 (Tocris Bioscience) was added to the cells 2 hours before LPS exposure at a 
concentration of 10 μ g/ml to inhibit LPS pathway receptor TLR4. Apoptosis was detected by flow cytomerty using 
Annexin V-FITC and 7-AAD double staining with FACSAria (BD Biosciences, Franklin Lakes, NJ). Cells positive 
for AnnexinV-FITC and negative for 7-AAD were deemed apoptotic. A total 1 × 104 cells were detected by FACS 
in each sample. Apoptosis was also detected by In-Cell Western as described below.
In-Cell Western. Podocytes cultured on black 96-well plates (PerkinElmer, Waltham, MA, USA) were fixed 
with 4% paraformaldehyde (Electron Microscopy Sciences) in PBS and permeabilized with 0.1% Triton X-100 
in PBS. Cells were incubated with rabbit anti-cleaved caspase-3 (Cell Signaling Technology), rabbit polyclonal 
anti-phospho-CDK2 (Cell Signaling Technology), or rabbit anti-CDK2 (Abcam) at room temperature for one 
hour, followed by IRDye 800 (LI-COR) donkey anti-rabbit IgG and 1 μ M DRAQ5TM (Thermo Fisher Scientific, 
Waltham, MA, USA) at RT for one hour. Detection and quantification were performed with an Odyssey Infrared 
Imager (LI-COR). DRAQ5TM was used for normalization.
Electron microscopy. Cortical mouse kidney samples were fixed in 1.5% glutaraldehyde, 3% PFA and 5% 
sucrose in 0.1 M phosphate buffer (pH 7.4) for 3 hours at room temperature, followed by postfixation in 1% 
osmium tetroxide for 2 h, stained en-bloc in 1% uranyl acetate in 10% ethanol for 1 h, dehydrated in ethanol and 
embedded in LX-112 (Ladd Research Industries, Williston, VT). Thin sections were stained with uranyl acetate 
and lead citrate and examined with a JEM-1400 Transmission Electron Microscope (Jeol, Tokyo, Japan) equipped 
with Olympus-SIS Morada digital camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany).
Treatment of podocytes with sera obtained from patients with diabetes. Male patients with T1D 
were recruited and examined by the Finnish Diabetic Nephropathy Study (FinnDiane; www.finndiane.fi). Serum 
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LPS activity levels were measured in 39 T1D patients with normal urinary albumin excretion (AER < 30 mg/24 h) 
as previously described13. Serum samples were selected from patients with highest (n = 6) and lowest (n = 6) 
LPS-activity (Supplementary Table S1). Differentiated human podocytes were treated with 10% human sera for 
72 hours. TLR pathway inhibitor, GIT27 (Tocris Bioscience) was added to the media at a concentration of 10 μ g/ml 
2 hours before addition of sera from patients with normoalbuminuria and high LPS activity. The expression level 
of CDK2 and apoptosis were analyzed by immunoblotting and In-Cell Western, respectively, as described above. 
The study protocols were approved by the local ethics committees and were in accordance with the declaration of 
Helsinki. The study subjects gave their written informed consent to their participation in the study.
Lentiviral infection to knock down CDK2 and PDK1. Human lentiviral pLKO1-shCDK2 vectors, 
CDK2A (CTCCTGGGCTGCAAATATTAT) and CDK2B (CCTCAGAATCTGCTTATTAAC) were used to 
knock down CDK2, and pLKO1-shPDK1 vector, PDK1A (GAAGGTATATTAGGACATTTG) (Biomedicum 
Genomics, University of Helsinki, Finland), to knock down PDK1 in differentiated human podocytes. Infection 
efficiency of the shRNA construct for PDK1 is described previously43. Human lentiviral empty pLKO1 vector 
(Biomedicum Genomics) was used as a control. For virus production, CMVDelta8.9 and phCMVg packaging 
plasmids (Biomedicum Genomics), together with CDK2A, CDK2B, PDK1A or empty vector, were transfected 
into HEK293FT cells (Invitrogen) with Lipofectamine2000 (Invitrogen). Virus-containing media were col-
lected 72 h later, filtrated through 0.45 μ m filter, and ultracentrifuged 85,000 × g at + 4 °C for 90 min. The viruses 
were resuspended in PBS and added to differentiated podocytes on day 10 or 11 of differentiation. Podocytes 
were incubated with viruses at + 37 °C for 10 min, followed by centrifugation 1360 × g at + 4 °C for 30 min. 
Virus-containing medium was replaced with regular medium after 24 h.
Roscovitine treatment. Differentiated human podocytes were cultured on black 96-well plates 
(PerkinElmer) at + 37 °C for 24 hours in RPMI medium containing or not 25 μ M roscovitine. The expression lev-
els of phosphorylated CDK2, CDK2 and cleaved caspase-3 were detected by In-Cell Western as described above.
Statistical methods. All cell culture experiments were carried out at least three times. All variables were 
presented as mean ± SD (cell culture experiments), or as mean ± SEM (animal experiments). The significance of 
differences between groups was determined by ANOVA or Students t-test (GraphPadPrism6, GraphPad Software 
Inc, La Jolla, CA, USA), and p-values of less than 0.05 were considered statistically significant.
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